INMUNOCEM

Phase 2Biologic

GGUSTAVO SALGUERO

INMUNOCEM is one of 9 biologic programs targeting Cell Therapy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cell TherapyNot yet recruiting

Cell TherapyPhase 2

Not yet recruiting

Competition

Competitive Landscape

11 competitors in Cell Therapy

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 2

5 2

Keytruda

Merck & Co.

Phase 2

1 3

Cytoxan

BBaxter Healthcare Corporation

Phase 2

5 4

Anti-CD19 CAR NK Cells

PPersonGen BioTherapeutics (Suzhou) Co., Ltd.

Phase 2

1 5

CD19 CAR-T Cells

CChongqing Precision Biotech Co., Ltd

Phase 1

1 6

INMUNOCEM

GGUSTAVO SALGUERO

Phase 2

1 7

Lymphodepletion Chemotherapy

MMarcela V. Maus, M.D.,Ph.D.

Phase 2

1 8

Cellular Therapy

Sanofi

Preclinical

1 9

ECT204 T Cells

EEureka Therapeutics Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cell Therapy1 trial

Cartilage Recovery in Adults With Knee Osteorthritis by Mesenchymal Cell Therapy: Randomized Trial of Radiologic and Clinical Outcomes

Not yet recruiting·GGUSTAVO SALGUERO·Phase 2·NCT05936060·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for INMUNOCEM. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — INMUNOCEM compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for INMUNOCEM. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GUSTAVO SALGUERO company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: GGUSTAVO SALGUERO

INMUNOCEM

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cell Therapy1 trial

References

Drug Info

Quick Facts

Related News